AC Immune director reports initial share and option holdings

AC Immune SA director Martin Zuegel filed an initial ownership report showing equity interests in the company.

Rhea-AI Filing Summary

AC Immune SA director Martin Zuegel filed an initial ownership report showing equity interests in the company. He holds share options over 52,577 and 32,061 common shares, each with an exercise price of $1.8400 per share and an expiration date of June 17, 2035. One option grant will fully vest on June 17, 2026, while the other will vest annually in three equal installments beginning on June 17, 2026. He also directly holds 38,272 common shares, which reflect common shares underlying outstanding restricted share units.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Zuegel Martin

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 84,638 contracts (Direct); Common Shares — 38,272 shares (Direct)

Footnotes (3)

1. F1. Reflects common shares underlying outstanding restricted share units.
2. F2. The share option will fully vest on June 17, 2026.
3. F3. The share option will vest annually in three equal installments beginning on June 17, 2026.

Key Figures

Common shares held: 38,272 shares Option underlying shares (grant 1): 52,577 shares Option underlying shares (grant 2): 32,061 shares +4 more

7 metrics

Common shares held 38,272 shares Direct common shares reflecting RSU-based holdings as of Form 3

Option underlying shares (grant 1) 52,577 shares Share option over common shares, exercise price $1.8400, expires June 17, 2035

Option underlying shares (grant 2) 32,061 shares Share option over common shares, exercise price $1.8400, expires June 17, 2035

Option exercise price $1.8400 per share Exercise price for both reported share option positions

Option expiration date June 17, 2035 Expiration date for both share option grants

Full vesting date (grant 1) June 17, 2026 Share option that will fully vest on this date

Start of annual vesting (grant 2) June 17, 2026 Share option vesting annually in three equal installments beginning this date

Key Terms

Share Option (right to buy), restricted share units, expiration date, vest annually in three equal installments, +1 more

5 terms

Share Option (right to buy) financial

"security_title: "Share Option (right to buy)" with underlying Common Shares"

restricted share units financial

"Reflects common shares underlying outstanding restricted share units."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

expiration date financial

"expiration_date: "2035-06-17T00:00:00.000Z" for the share options"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest annually in three equal installments financial

"The share option will vest annually in three equal installments beginning on June 17, 2026."

beneficial ownership financial

"These positions reflect his initial beneficial ownership as a director."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity holdings does AC Immune (ACIU) director Martin Zuegel report on this Form 3?

Martin Zuegel reports direct ownership of 38,272 common shares and two share option positions over 52,577 and 32,061 common shares. These positions reflect his initial beneficial ownership as a director of AC Immune SA.

What are the key terms of Martin Zuegel’s AC Immune (ACIU) share options?

Zuegel’s share options cover 52,577 and 32,061 common shares at an exercise price of $1.8400 per share. Both option grants have an expiration date of June 17, 2035, providing long-dated potential equity exposure.

How and when do Martin Zuegel’s AC Immune (ACIU) share options vest?

One share option grant will fully vest on June 17, 2026. The other grant will vest annually in three equal installments beginning on June 17, 2026. These vesting schedules tie his potential equity benefits to continued service.

What does the 38,272 common shares figure represent for AC Immune (ACIU) director Zuegel?

The 38,272 common shares reflect common shares underlying outstanding restricted share units. This means his reported direct common share holdings are linked to RSUs that can settle into shares, aligning his compensation with AC Immune’s equity performance.

Does this AC Immune (ACIU) Form 3 show any recent share purchases or sales by Martin Zuegel?

The Form 3 presents holding entries only and does not show explicit buy or sell transactions. It establishes Zuegel’s initial ownership in common shares and options as of the reported date, rather than recording new market trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:51 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zuegel Martin

(Last) (First) (Middle)

EPFL INNOVATION PARK

BUILDING B

(Street)

LAUSANNE SWITZERLAND 1015

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	38,272(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	06/17/2035	Common Shares	52,577	$1.84	D
Share Option (right to buy)	(3)	06/17/2035	Common Shares	32,061	$1.84	D

Explanation of Responses:

1. Reflects common shares underlying outstanding restricted share units.

2. The share option will fully vest on June 17, 2026.

3. The share option will vest annually in three equal installments beginning on June 17, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthias Maurer, attorney-in-fact for Martin Zuegel	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)